Novo Insulin Pen Retreat Risks Drug Access to Kids with Diabetes, Report Says

Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here.

Novo Nordisk A/S’s decision to stop making insulin pens will narrow treatment options for children with diabetes unless non-patented drugmakers such as Biocon Ltd. step in to plug the gap in a $34 billion market.